Traders should anticipate near-term dilution from a significant share offering, which typically pressures stock prices in biotech. Monitor whether the use of proceeds signals a cash crunch or strategic expansion. The $2.00 price point may indicate weak investor demand if it's at or below market price.
Price Chart
Executive Summary
Allogene Therapeutics priced an underwritten public offering of 87.5 million shares at $2.00 per share, raising $175 million in gross proceeds before expenses. The company also granted underwriters a 30-day option to purchase up to 13.1 million additional shares. Proceeds will fund general corporate purposes including clinical trials and R&D.
Key Financial Metrics
Key Facts
- Allogene Therapeutics is offering 87,500,000 shares at $2.00 per share, raising $175 million in gross proceeds.
- Underwriters have a 30-day option to purchase up to 13,125,000 additional shares.
- Net proceeds will be used for general corporate purposes, including clinical trials, R&D, and capital expenditures.
- Goldman Sachs & Co. LLC, Jefferies, and TD Cowen are joint bookrunners.
- The offering is expected to close on or about April 16, 2026, subject to customary conditions.
Financial Impact
$175 million in gross proceeds, with potential for $26.25 million additional if the over-allotment is exercised
Risk Factors
- Significant equity dilution from issuing ~87.5M new shares (pre-offering float was ~370M, implying ~24% dilution)
- Potential downward pressure on stock price due to oversupply of shares and insider selling ahead of the deal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274082 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.21 (−3.20%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.21 (−38.89%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.21 (−40.39%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.21 (+42.11%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.21 (−38.58%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.21 (+41.55%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.21 (−44.24%) |
May 28, 2026 21w ago | Press Release | $2.17 $2.15 | ▼ −0.92% | ▼ −1.20% | $1.21 (−44.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers